GlassScriptPhysician profile
Brian Brennan
NPI 1487298725
$9,045.02
in general payments reported to CMS, 2019-2025
29 companies · $2,772 in 2025
The $2,772 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $940 · 2023: $2,084 · 2024: $2,887 · 2025: $2,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,382 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,382.39 |
| Education | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,288.45 | 2021-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $1,481.12 | 2021-2025 | Biktarvy |
| Theratechnologies INC. | $752.52 | 2021-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Merck Sharp & Dohme LLC | $708.61 | 2021-2025 | Pifeltro, Delstrigo, Isentress |
| Lilly USA, LLC | $597.30 | 2023-2025 | Mounjaro, Zepbound |
| Janssen Biotech, INC. | $542.74 | 2022-2023 | Symtuza |
| Emd Serono, INC. | $389.34 | 2021-2024 | Serostim, Serostim |
| Astrazeneca Pharmaceuticals LP | $382.87 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Napo Pharmaceuticals INC | $368.60 | 2021-2025 | Mytesi |
| Novo Nordisk INC | $329.36 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $258.69 | 2022-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $206.71 | 2021-2024 | Rexulti, Abilify Maintena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.30 | 2021-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.93 | 2024-2025 | Caplyta |
| Abbvie INC. | $72.96 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $72.69 | 2023 | |
| Xeris Pharmaceuticals, INC. | $59.80 | 2023 | Keveyis |
| Acerus Pharmaceuticals Corporation | $59.50 | 2021-2022 | |
| Antares Pharma, INC. | $48.28 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Hologic Sales and Service, LLC | $47.78 | 2024-2025 | Thinprep 2000 Processor, Aptima, Third Wave |
| Vbi Vaccine (Delaware) INC. | $38.57 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.03 | 2022 | |
| Exact Sciences Corporation | $19.60 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $18.85 | 2022 | |
| Atricure, INC. | $17.56 | 2024 | |
| Janssen Scientific Affairs, LLC | $17.54 | 2023 | Symtuza |
| Insmed, INC. | $15.98 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.16 | 2024 | Trintellix |
| Pfizer INC. | $14.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.